The winner of the 1996 Nobel Prize in Physiology and Medicine, Peter C. Doherty, highlighted the effectiveness of the Sputnik V vaccine against the coronavirus. Likewise, it confirmed that the possible dose adjustments before the new variants of the virus will not cause problems for its creators.
In statements to the Russian news agency TASSDoherty emphasized the use of viral vectors in the manufacture of the drug developed by the Gamaleya center.
“The effectiveness of the Sputnik V vaccine – more than 90% – looks very good, and also, Russia has a long history of developing good vaccines. The strategy for using two adenovirus vectors makes sense and is, as I understand it, used in Sputnik. Of course, if the virus changes significantly as a result of the mutation, the vaccine makers will have to “correct the drug a little bit, but it won’t be difficult,” noted the specialist.
The Lancet published the results of the Russian vaccine: the effectiveness is 91.6%
This is according to an interim analysis of phase 3 of the clinical trials, published in the medical journal on Tuesday, February 2 The LancetRussian Sputnik V vaccine against coronavirus has an overall efficacy of 91.6%.
The publication points out that these studies enrolled 21,977 adults, who were randomly assigned to the vaccine group (16,501 people) and the placebo group (5,746) between September 7 and November 24, 2020.
A total of 19,866 volunteers received the two doses required for immunization, and among them only 78 cases of Covid-19 were confirmed.